HR Execs on the Move

Rebus Biosystems

www.rebusbio.com

 
Advanced imaging, fluidics, chemistry and bioinformatics. Innovative, robust tools for spatial omics without compromise. Rebus Esper platform available now.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.rebusbio.com
  • 2255, Martin Avenue
    Santa Clara, CA USA 95050
  • Phone: 408.988.2700

Executives

Name Title Contact Details

Similar Companies

Bryan LGH

Bryan LGH is a Lincoln, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Custom Biogenic Systems

Custom Biogenic Systems is a Romeo, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Genomatica

Geno is harnessing biology to remake everyday products and materials built by and for the planet. In response to the urgent climate crisis, Geno is developing and scaling sustainable materials derived from plant- or waste-based feedstocks instead of fossil fuels. Geno`s technology, built over the last 20 years, now drives materials and ingredients in applications ranging from cosmetics, carpets, to home cleaners, apparel and more.

Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities.

Patara Pharma

Patara Pharma is a biopharmaceutical company developing a new therapy for the treatment of allergic and immunologic diseases and conditions that affect orphan patient populations. We completed a Phase 1 clinical trial with favorable results and have initiated Phase 2 clinical trials for several undisclosed indications that will read-out by the end of 2015.